COGTCogent Biosciences, Inc.

$36.71

$36.71

$10.9352 weeks$42.84

The financials

Cogent Biosciences, Inc. by the numbers

Cogent Biosciences, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statement	Q2 2026	Q2 2025	Change
Operating income	−$103M	−$76M	n/a
Net income	−$96M	−$74M	n/a
Diluted EPS	−$0.52	−$0.53	n/a

Biotechnology

Ranks #120 of 145 by Smart Score

Scholar Rock Holding Corporation

CG Oncology, Inc.

PTC Therapeutics, Inc.

Belite Bio, Inc

Definium Therapeutics, Inc.

Ligand Pharmaceuticals Incorporated